Search the Newsreel

Rallybio Corp (RLYB) Institutional Confidence

Rallybio Corp (RLYB) has an institutional shareholding score of 5.00, placing it 132nd out of 386 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 65.82%, a slight decrease of 1.97% quarter-over-quarter. Andreas Halvorsen is the largest institutional shareholder, holding …

Cybin Ord Shs (HELP) Institutional Confidence

This article from TradingKey focuses on the institutional confidence in Cybin Ord Shs (HELP). It highlights key institutional shareholders and their recent activity, showing significant increases in shares held by top firms like Point72 Asset Management and OrbiMed Advisors. The data provided includes the …

Yuanbao Inc (YB) Income Statement

This article presents the quarterly and annual income statements for Yuanbao Inc (YB), detailing financial performance metrics such as total revenue, gross profit, operating expenses, and net income. It also includes frequently asked questions about how to interpret the income statement data on TradingKey, …

YB|Yuanbao Inc|Price:13.320|Chg%:-0.110

This article provides a detailed financial overview of Yuanbao Inc (YB), including its stock performance, key financial indicators, and earnings reports. It presents the company's income statement, balance sheet, and cash flow statement, highlighting revenue, EPS, net profit, and asset figures for various fiscal …

CISO Global Inc (CISO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides an overview of CISO Global Inc (CISO), including its stock performance and market capitalization. It highlights that detailed revenue breakdown data by business segments and regions are not yet disclosed by the company. The page displays placeholders for future …

CISO Global Inc (CISO) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical dividend and stock split information for CISO Global Inc (CISO). It indicates that CISO has distributed no dividends over the past five years and details a series of 15-to-1 merger-related stock splits that occurred on March 6, 2024. The stock's …

Cybertech Systems Q1 Results: Unaudited Financials for Q1FY26 Published

Cybertech Systems revenue rises 17.6% in Q1FY27; net profit up 15.9%

HELP|Cybin Ord Shs|Price:7.620|Chg%:-0.110

This page provides a detailed overview of Cybin Ord Shs (HELP), including its current stock price, market capitalization, performance metrics, and key financial figures. It also features analyst ratings, peer comparisons, technical indicators, and major shareholders, alongside frequently asked questions about the company.

CISO Balance Sheet

This article presents the quarterly and annual balance sheets for CISO Global Inc, allowing users to assess the company's financial health, analyze fundamentals, and calculate key ratios for liquidity, leverage, and return on equity. It includes detailed financial figures for assets, liabilities, and shareholders' …

Cybin Inc. Revenue Breakdown – BOATS:HELP

This article provides a basic financial overview of Cybin Inc. (HELP) on the TradingView platform, specifically focusing on its revenue breakdown. It indicates the market status as closed with no trades and highlights functionality for viewing financials, documents, news, and community discussions. The article …

PT Bank Maybank Indonesia Tbk Class A Revenue Breakdown – IDX:BNII

Quantum Cyber N.V. Revenue Breakdown – NASDAQ:QUCY

ImmunityBio says it is ‘incredibly committed’ to Dunkirk

ImmunityBio affirms its strong commitment to its Dunkirk, NY facility, which it leased after Athenex's bankruptcy. The company is investing significantly in renovations to transform the site into a pharmaceutical manufacturing plant, with operations expected by 2028. This commitment follows FDA approval for their …

Yuanbao Inc. Revenue Breakdown – NASDAQ:YB

This article provides a revenue breakdown for Yuanbao Inc. (NASDAQ: YB), highlighting its top-performing segment and primary geographic contributor. Last year, the company generated $625.19 million USD in revenue, with Marketing and Related Analytics Services being the leading segment and China providing the largest …

ImmunityBio Inks Partnerships To Launch Cancer Drug In Saudi Arabia Amid Expansion Efforts

ImmunityBio has partnered with Biopharma and Cigalah to launch its immunotherapy Anktiva in Saudi Arabia, with aspirations to expand across the broader Middle East and North Africa region. The company also established a new unit in Saudi Arabia to support distribution and commercialization, following …

Built Cybernetics plc Revenue Breakdown – LSE:BUC

CISO Global Inc (CISO) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of CISO Global Inc (CISO), highlighting its current valuation score and P/E ratio within the Software & IT Services industry. The company's valuation score is 8.64, ranking 191 out of 484 in its sector, and its P/E ratio …

Rallybio Corp (RLYB) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Rallybio Corp (RLYB), detailing its current price momentum score, support and resistance levels, and a comprehensive breakdown of technical indicators and moving averages. The analysis suggests a "Neutral" signal for the stock based on these indicators, noting …

Cybertech Systems & Software consolidated net profit rises 16.03% in the June 2026 quarter

Cybin D/B/A Helus Pharma (HELP) Stock Price, News, Quote & History

Cybin D/B/A Helus Pharma (HELP) is a clinical-stage pharmaceutical company focused on developing therapies for psychiatric and neurological conditions. The company's stock is currently trading at $7.62, down 1.42% at close, with a 1-year target estimate of $37.55. Key pipeline assets include HLP003 for …

Yuanbao (YB) Q1 2026 earnings summary

Yuanbao (YB) reported strong Q1 2026 results with revenue up 35.6% year-over-year to RMB 1.32 billion and net income up 31.4% to RMB 388 million. The company launched AI-powered insurance applications and maintained robust cash reserves. The board approved an annual cash dividend and …

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ImmunityBio, Inc. (IBRX) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing allegations against ImmunityBio, Inc. (IBRX). The firm is encouraging shareholders who purchased ImmunityBio securities before January 19, 2026, and continue to hold them, to assist with the investigation. The firm operates …

H.C. Wainwright Maintains Cybin(HELP.US) With Buy Rating, Raises Target Price to $70

H.C. Wainwright has reiterated its Buy rating on Cybin (HELP.US) and increased its price target to $70. This updated guidance reflects a positive outlook from the analyst firm regarding Cybin's future performance.

Chief Financial Officer Greg Cavers Sold A Bunch Of Shares In Cybin

Cybin's Chief Financial Officer, Greg Cavers, recently sold US$431k worth of stock at US$6.10 per share, representing 45% of his holding. This insider sale, occurring below the current market price of US$7.25, raises concerns, although the company's insider ownership at 12% is considered sufficient …

Yuanbao (YB) Registration Filing Summary

Yuanbao (YB) is an online insurance distributor in China that uses technology, data analytics, and AI to offer personalized products. The company reported significant revenue growth and achieved profitability in 2023, generating net income of RMB205.2 million. Yuanbao plans to allocate its IPO proceeds …

CISO Global Advances AI Software-Led Cybersecurity Strategy with FedRAMP-Certified TiGRIS GRC Platform

CISO Global announced a significant step in its transition to a software-led cybersecurity company by expanding its FedRAMP-certified TiGRIS GRC platform. TiGRIS offers compliance automation, automated evidence collection, and risk-based workflows, with plans to integrate generative AI for enhanced capabilities. This platform, combined with …

CISO Global's TiGRIS Automates Evidence Collection for Compliance

CISO Global (NASDAQ: CISO) announced the expansion of its FedRAMP-certified TiGRIS governance, risk, and compliance (GRC) platform, marking a strategic shift towards AI-powered cybersecurity. TiGRIS centralizes compliance intelligence and automates evidence collection, with plans to integrate generative AI for enhanced analysis and risk visibility. …

CISO Global expands TiGRIS compliance automation platform By Investing.com

CISO Global has announced the expansion of its FedRAMP-certified compliance automation platform, TiGRIS. The platform offers compliance intelligence, automated evidence collection, and risk-based workflows, with plans to integrate generative AI capabilities soon. The company aims to provide more robust governance solutions beyond basic policy …

Cybin (NEOE:HELP) Stock Forecast & Analyst Predictions

Cybin (NEOE:HELP) is forecast to grow earnings by 52.4% and revenue by 63.1% per annum, although analysts no longer expect the company to break even in the foreseeable future, projecting significant losses. Recent developments include the completion of enrollment for a Phase 3 study …

Moneyboxx Finance Share Price Forecast: 3 Year Outlook to 2030

Moneyboxx Finance raises ₹500 million via NCDs in FY27

ImmunityBio: Revisiting My Bearish Call After A 250% Rise (Upgrade) (NASDAQ:IBRX)

ImmunityBio (IBRX) receives a cautious buy rating from an analyst who previously held a bearish stance, following a 250% stock rise. The upgrade is driven by Anktiva's strong efficacy in NMIBC and its potential in broader oncology indications, with significant future revenue reflected in …

ImmunityBio (IBRX) Could Be 41% Below Fair Value After Anktiva Optimism

ImmunityBio (IBRX) has seen significant share gains due to investor optimism surrounding its bladder cancer therapy, Anktiva. Despite recent slight cooling in trading, the stock is considered 40.9% undervalued with a fair value of $13 per share, compared to its last close of $7.68. …

ImmunityBio (NASDAQ:IBRX) stock faces July 24 warrant-expiry test after Friday rebound

ImmunityBio (NASDAQ:IBRX) faces a warrant expiry test on July 24, with up to 6.4 million new shares potentially entering the market from 2023 warrants. These warrants, with an exercise price of $3.2946, were deeply in the money at Friday's closing price of $7.68. Full …

Quantum Cyber Secures Bridgeport Facility for Defense Production